Literature DB >> 25178878

Diagnosis and management of solid benign liver lesions.

Jacques Belghiti1, François Cauchy1, Valérie Paradis2, Valérie Vilgrain3.   

Abstract

More and more asymptomatic benign liver tumours are discovered incidentally and can be divided into regenerative lesions and true neoplastic lesions. The most common regenerative lesions include hemangioma, focal nodular hyperplasia and inflammatory pseudotumours of the liver. Neoplastic lesions include hepatocellular adenomas and angiomyolipomas. Regenerative lesions rarely increase in volume, do not yield a higher risk of complications and usually do not require treatment. By contrast, hepatocellular adenomas and angiomyolipomas can increase in volume and are associated with a risk of complications. Large hepatocellular adenomas (>5 cm in diameter) are undoubtedly associated with a risk of bleeding and malignant transformation, particularly the inflammatory (also known as telangiectatic) and β-catenin mutated subtypes. Accurate diagnosis needs to be obtained to select patients eligible for surgical resection. MRI has markedly improved diagnosis and can identify the major hepatocellular adenomas subtypes. The use of biopsy results to inform the indication for resection remains questionable. However, when diagnosis remains uncertain after imaging, percutaneous biopsy could help improve diagnostic accuracy.

Entities:  

Mesh:

Year:  2014        PMID: 25178878     DOI: 10.1038/nrgastro.2014.151

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  26 in total

1.  Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.

Authors:  Edouard Reizine; Maxime Ronot; Frederic Pigneur; Yvonne Purcell; Sebastien Mulé; Marco Dioguardi Burgio; Julien Calderaro; Giuliana Amaddeo; Alexis Laurent; Valérie Vilgrain; Alain Luciani
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

Review 2.  Computed Tomography Versus Magnetic Resonance Imaging for Hepatic Lesion Characterization/Diagnosis.

Authors:  Khaled Y Elbanna; Ania Z Kielar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 3.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

4.  Inflammation-associated upregulation of the sulfated steroid transporter Slc10a6 in mouse liver and macrophage cell lines.

Authors:  Astrid Kosters; Demesew F Abebe; Julio C Felix; Paul A Dawson; Saul J Karpen
Journal:  Hepatol Res       Date:  2015-11-19       Impact factor: 4.288

5.  Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment.

Authors:  Laihui Luo; Tao Wang; Mengting Cheng; Xian Ge; Shengjiang Song; Guoqing Zhu; Yongqiang Xiao; Wei Deng; Jin Xie; Renfeng Shan
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-05       Impact factor: 4.553

6.  National trends in the use of surgery for benign hepatic tumors in the United States.

Authors:  Yuhree Kim; Neda Amini; Jin He; Georgios A Margonis; Matthew Weiss; Christopher L Wolfgang; Martin Makary; Kenzo Hirose; Gaya Spolverato; Timothy M Pawlik
Journal:  Surgery       Date:  2015-03-11       Impact factor: 3.982

Review 7.  Focal liver lesions: Practical magnetic resonance imaging approach.

Authors:  António P Matos; Fernanda Velloni; Miguel Ramalho; Mamdoh AlObaidy; Aruna Rajapaksha; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-08-08

8.  Outcome after a liver resection of benign lesions.

Authors:  Katrin Hoffmann; Michael Unsinn; Ulf Hinz; Karl Heinz Weiss; Nina Waldburger; Thomas Longerich; Boris Radeleff; Peter Schirmacher; Markus W Büchler; Peter Schemmer
Journal:  HPB (Oxford)       Date:  2015-09-03       Impact factor: 3.647

9.  Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.

Authors:  E Reizine; M Ronot; M Ghosn; J Calderaro; N Frulio; P Bioulac-Sage; H Trillaud; V Vilgrain; V Paradis; A Luciani
Journal:  Eur Radiol       Date:  2020-11-04       Impact factor: 5.315

Review 10.  Current Approaches in the Management of Hepatic Adenomas.

Authors:  Diamantis I Tsilimigras; Amir A Rahnemai-Azar; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Demetrios Moris; Eleftherios Spartalis; Jordan M Cloyd; Sharon M Weber; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-08-14       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.